Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer

Clinical trial NCT04120454 · COMPLETED

Trial details

NCT number: NCT04120454
Sponsor: Ohio State University Comprehensive Cancer Center
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Lung Non-Small Cell Carcinoma Recurrent Lung Non-Small Cell Carcinoma Stage IV Lung Cancer AJCC v8 Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8

Start date: 2020-06-17
Primary completion: 2023-08-19
Enrollment: 6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.